MLTX

18.23

0.11% 0.04

Handel nachbörslich: 18.23

Moonlake Immunotherapeutics (MLTX)

Überblick Nachrichten Preisverlauf Optionskette Financials Warum fällt MLTX? Forum Prognose

Schlusskurs vom Vortag:

$18.19

Offen:

$18.19

24-Stunden-Volumen:

574.98K

Relative Volume:

0.54

Marktkapitalisierung:

$1.34B

Einnahmen:

Nettoeinkommen (Verlust:

$-230.32M

KGV:

-5.1703

EPS:

-3.5259

Netto-Cashflow:

$-196.04M

1W Leistung:

+11.24%

1M Leistung:

+6.00%

6M Leistung:

+31.96%

1J Leistung:

-53.22%

1-Tages-Spanne:

$17.94

$18.58

1-Wochen-Bereich:

$16.53

$18.75

52-Wochen-Spanne:

$5.95

$62.75

Moonlake Immunotherapeutics Stock (MLTX) Company Profile

Firmenname

Moonlake Immunotherapeutics

Sektor

Healthcare (1113)

Branche

Biotechnology (618)

Telefon

41 41 510 8022

Adresse

DORFSTRASSE 29, ZUG

Mitarbeiter

130

Twitter

Nächster Verdiensttermin

2026-05-11

Neueste SEC-Einreichungen

MLTX's Discussions on Twitter

Compare MLTX vs VRTX, REGN, ARGX, ALNY, RVMD

Aktien	Preis	Marktkapitalisierung	Umsatz	Nettogewinn	Free Cashflow	ENV
MLTX Moonlake Immunotherapeutics	18.23	1.34B	0	-230.32M	-196.04M	-3.5259
VRTX Vertex Pharmaceuticals Inc	435.92	110.28B	12.34B	4.34B	3.71B	16.87
REGN Regeneron Pharmaceuticals Inc	634.42	66.98B	14.92B	4.42B	3.79B	41.04
ARGX Argen X Se Adr	808.61	50.15B	4.16B	1.29B	734.26M	19.58
ALNY Alnylam Pharmaceuticals Inc	295.50	39.71B	4.29B	577.22M	641.34M	4.2086
RVMD Revolution Medicines Inc	154.89	32.22B	742.00K	-1.37B	-1.07B	-7.0731

Moonlake Immunotherapeutics Stock (MLTX) Upgrades & Downgrades

Datum	Aktion	Analytiker	Ratingänderung
2026-03-23	Hochstufung	Wolfe Research	Underperform → Outperform
2026-03-19	Hochstufung	Rothschild & Co Redburn	Neutral → Buy
2026-01-15	Herabstufung	Goldman	Neutral → Sell
2026-01-09	Hochstufung	BTIG Research	Neutral → Buy
2025-11-03	Hochstufung	H.C. Wainwright	Neutral → Buy
2025-10-02	Herabstufung	H.C. Wainwright	Buy → Neutral
2025-10-01	Herabstufung	Goldman	Buy → Neutral
2025-09-30	Herabstufung	Citigroup	Buy → Neutral
2025-09-30	Herabstufung	Wolfe Research	Outperform → Underperform
2025-09-29	Herabstufung	BTIG Research	Buy → Neutral
2025-09-29	Herabstufung	Jefferies	Buy → Hold
2025-09-29	Herabstufung	RBC Capital Mkts	Outperform → Sector Perform
2025-09-29	Herabstufung	Stifel	Buy → Hold
2025-07-28	Eingeleitet	Rothschild & Co Redburn	Neutral
2025-05-19	Hochstufung	Wolfe Research	Peer Perform → Outperform
2025-03-18	Eingeleitet	RBC Capital Mkts	Outperform
2025-01-17	Hochstufung	Goldman	Neutral → Buy
2024-11-05	Fortgesetzt	Wedbush	Outperform
2024-08-26	Herabstufung	Wolfe Research	Outperform → Peer Perform
2024-06-25	Eingeleitet	Oppenheimer	Outperform
2024-04-02	Eingeleitet	Goldman	Neutral
2024-02-15	Eingeleitet	Wolfe Research	Outperform
2023-12-08	Eingeleitet	Citigroup	Buy
2023-11-02	Eingeleitet	Stifel	Buy
2023-09-14	Herabstufung	Bryan Garnier	Buy → Neutral
2023-08-31	Eingeleitet	Needham	Buy
2023-06-15	Eingeleitet	Barclays	Equal Weight
2023-05-01	Eingeleitet	Guggenheim	Buy
2023-03-22	Eingeleitet	Wedbush	Outperform
2023-03-09	Eingeleitet	BTIG Research	Buy
2023-02-14	Eingeleitet	Cantor Fitzgerald	Overweight
2023-02-02	Eingeleitet	Bryan Garnier	Buy
2022-11-11	Eingeleitet	Jefferies	Buy
2022-08-25	Eingeleitet	SVB Leerink	Outperform
2022-07-21	Eingeleitet	H.C. Wainwright	Buy
2022-07-07	Eingeleitet	Cowen	Outperform

Alle ansehen

Moonlake Immunotherapeutics Aktie (MLTX) Neueste Nachrichten

02:26 AM

HC Wainwright & Co. Maintains MoonLake Immunotherapeutics (MLTX) Buy Recommendation - MSN

02:26 AM

May 25, 2026

How Moonlake Immunotherapeutics (MLTX) Affects Rotational Strategy Timing - Stock Traders Daily

May 25, 2026

May 24, 2026

MoonLake clears a key regulatory hurdle, and shares rocket - MSN

May 24, 2026

Should FDA Alignment on Sonelokimab’s HS Label Strategy Require Action From MoonLake Immunotherapeutics (MLTX) Investors? - simplywall.st

May 24, 2026

MLTX stock soars overnight after FDA backs skin drug filing — analyst sees over 300% upside on 'best-in-class' label - MSN

May 24, 2026

May 22, 2026

MoonLake ImmunotherapeuticsClass A Ordinary Shares (NQ: MLTX - The Chronicle-Journal

May 22, 2026

May 21, 2026

What Do MoonLake's Latest Week 40 HS Results Really Mean for Investors? - Kavout

May 21, 2026

MLTX stock garners retail attention on buyout speculation, positive skin condition trial data - MSN

May 21, 2026

May 20, 2026

MoonLake’s lead asset shows durability in late-stage HS studies - MSN

May 20, 2026

MoonLake (MLTX) shares gain after positive FDA meeting on sonelokimab filing - MSN

May 20, 2026

May 19, 2026

MLTX Technical Analysis | Trend, Signals & Chart Patterns | MOONLAKE IMMUNOTHERAPEUTICS (NASDAQ:MLTX) - ChartMill

May 19, 2026

May 18, 2026

LifeSci Capital Maintains MoonLake Immunotherapeutics(MLTX.US) With Buy Rating, Maintains Target Price $33 - 富途牛牛

May 18, 2026

May 16, 2026

Assessing MoonLake Immunotherapeutics (MLTX) Valuation After Positive FDA Pre BLA Outcome For Sonelokimab - simplywall.st

May 16, 2026

May 15, 2026

FDA aligns with MoonLake on lead drug submission plans, stock soars - MSN

May 15, 2026

Cormorant Asset Management and Bihua Chen report 6.25% stake in MoonLake (MLTX) - Stock Titan

May 15, 2026

May 14, 2026

(MLTX) and the Role of Price-Sensitive Allocations - Stock Traders Daily

May 14, 2026

MLTX Stock Chart | MOONLAKE IMMUNOTHERAPEUTICS (NASDAQ:MLTX) - ChartMill

May 14, 2026

May 13, 2026

Insider Sell Alert: Matthias Bodenstedt Sells Shares of MoonLake Immunotherapeutics (MLTX) - GuruFocus

May 13, 2026